Figure 8
From: Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ
Inhibition of the Cdk5-mediated phosphorylation of PPARγ at Ser245 by lobeglitazone or rosiglitazone. (a) In vitro Cdk5 assay results with PPARγ LBD incubated with rosiglitazone or lobeglitazone in a dose-dependent manner. pPPARγ, phosphorylated PPARγ. (b) Quantification of PPARγ phosphorylation compared with total PPARγ in vitro. Rosi, rosiglitazone; Lobe, lobeglitazone.
